Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Receivables - OtherRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Kezar Life Sciences (KZR) Other Accumulated Expenses (2021 - 2023)

Kezar Life Sciences (KZR) has disclosed Other Accumulated Expenses for 3 consecutive years, with $106000.0 as the latest value for Q4 2023.

  • For Q4 2023, Other Accumulated Expenses fell 60.0% year-over-year to $106000.0; the TTM value through Dec 2023 reached $106000.0, down 60.0%, while the annual FY2023 figure was $106000.0, 60.0% down from the prior year.
  • Other Accumulated Expenses hit $106000.0 in Q4 2023 for Kezar Life Sciences, down from $265000.0 in the prior quarter.
  • Across five years, Other Accumulated Expenses topped out at $280000.0 in Q3 2021 and bottomed at $7000.0 in Q2 2021.
  • Average Other Accumulated Expenses over 3 years is $128500.0, with a median of $102500.0 recorded in 2021.
  • Year-over-year, Other Accumulated Expenses soared 167.68% in 2022 and then crashed 60.0% in 2023.
  • Kezar Life Sciences' Other Accumulated Expenses stood at $99000.0 in 2021, then skyrocketed by 167.68% to $265000.0 in 2022, then plummeted by 60.0% to $106000.0 in 2023.
  • According to Business Quant data, Other Accumulated Expenses over the past three periods came in at $106000.0, $265000.0, and $99000.0 for Q4 2023, Q4 2022, and Q4 2021 respectively.